Climb Bio, Inc.
- Biotech or pharma, therapeutic R&D
Climb Bio is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. Our lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. , we are also developing CLYM116, a preclinical stage anti-APRIL (A PRoliferation-Inducing Ligand) mAb for patients with IgA nephropathy (IgAN) and other B-cell mediated diseases.
PLEASE NOTE WE WILL NOT BE TAKING MEETINGS FROM SERVICE PROVIDERS
Address
Wellesley HillsMassachusetts
United States
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}